PALO ALTO, Calif., Jan. 4 /PRNewswire-FirstCall/ -- Telik, Inc. announced that its chairman and chief executive officer, Michael M. Wick, M.D., Ph.D., will provide a corporate overview and update at the 24th Annual JPMorgan Healthcare Conference in San Francisco on Tuesday, January 10, 2006 at 4:00 pm Pacific time (7:00 pm Eastern time). A live webcast of the presentation will be available via the Telik website, www.telik.com, and an archived replay of the webcast will be available on the Telik website through January 17, 2006.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA(TM) (TLK286), a tumor-activated small molecule product candidate. TELCYTA is in three Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in Phase 2 clinical development in myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, Inc., +1-650-845-7728, or cdeguzman@telik.com
Web site: http://www.telik.com/
